News Focus
News Focus
icon url

Hosai

10/09/24 8:28 AM

#471052 RE: Investor2014 #471051

What drug would you recommend to early AD patients instead considering Anavex' "strictly failed trials"?
icon url

ohsaycanyousee82

10/09/24 8:45 AM

#471054 RE: Investor2014 #471051

The entire basis of your pre revenue baby bio investment strategy is the notion of significantly undervalued companies where you look for a couple home runs to more than offset larger numbers of losers.
icon url

ignatiusrielly35

10/09/24 8:53 AM

#471056 RE: Investor2014 #471051

Something higher than a market cap of $430m. The AD trial did not fail. The results are better than for other approved drugs, with better safety, ease of administration, cost, etc., and that’s all that should really matter. The fact that they missed on an endpoint that most now consider to be an immaterial one is a technicality.